Journal Article

Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma

Kuramitsu, Mimi, Nishimura, Yuka, Kanemaru, Ayumi, Shinriki, Satoru, Nakayama, Hideki, Ozeki, Kazuya, Saito, Hideyuki, Takano, Kanako, Suenaga, Naoki, Jono, Hirofumi, Komure, Kanae, Yoshida, Ryoji

2019

Overview

Cisplatin is one of the most effective chemotherapeutic agents commonly used for several malignancies including oral squamous cell carcinoma (OSCC). Although cisplatin resistance is a major obstacle to effective treatment and is associated with poor prognosis of OSCC patients, the molecular mechanisms by which it develops are largely unknown. Cylindromatosis (CYLD), a deubiquitinating enzyme, acts as a tumor suppressor in several malignancies. Our previous studies have shown that loss of CYLD expression in OSCC tissues is significantly associated with poor prognosis of OSCC patients. Here, we focused on CYLD expression in OSCC cells and determined whether loss of CYLD expression is involved in cisplatin resistance in OSCC and elucidated its molecular mechanism. In this study, to assess the effect of CYLD down-regulation on cisplatin resistance in human OSCC cell lines (SAS), we knocked-down the CYLD expression by using CYLD-specific siRNA. In cisplatin treatment, cell survival rates in CYLD knockdown SAS cells were significantly increased, indicating that CYLD down-regulation caused cisplatin resistance to SAS cells. Our results suggested that cisplatin resistance caused by CYLD down-regulation was associated with the mechanism through which both the reduction of intracellular cisplatin accumulation and the suppression of cisplatin-induced apoptosis via the NF-κB hyperactivation. Moreover, the combination of cisplatin and bortezomib treatment exhibited significant anti-tumor effects on cisplatin resistance caused by CYLD down-regulation in SAS cells. These findings suggest the possibility that loss of CYLD expression may cause cisplatin resistance in OSCC patients through NF-κB hyperactivation and may be associated with poor prognosis in OSCC patients.

• Publisher: MDPI AG,MDPI
• Subject: Antineoplastic Agents - pharmacology / Apoptosis / Breast cancer / Cancer therapies / Carcinoma, Squamous Cell - drug therapy / Carcinoma, Squamous Cell - metabolism / Carcinoma, Squamous Cell - pathology / Cell Proliferation / Chemotherapy / Cisplatin - pharmacology / Deubiquitinating Enzyme CYLD - antagonists & inhibitors / Deubiquitinating Enzyme CYLD - genetics / Deubiquitinating Enzyme CYLD - metabolism / Drug dosages / Drug Resistance, Neoplasm / Enzymes / Gene Expression Regulation, Neoplastic - drug effects / Humans / Kinases / Liver cancer / Medical prognosis / Mouth Neoplasms - drug therapy / Mouth Neoplasms - metabolism / Mouth Neoplasms - pathology / NF-kappa B - genetics / NF-kappa B - metabolism / Oral cancer / RNA Interference / Tumor Cells, Cultured / Tumors